Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab Extension in Behçet's Uveitis
NCT01093846Phase 3Terminated
- Sponsor
- Novartis
- Start
- Mar 2010
- Primary completion
- Jan 2011
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in Behçet's disease (BD) and uveitis (3 arms), sponsored by Novartis. Primary endpoint: Rate of Recurrent Ocular Exacerbations at 62 weeks. Started Mar 2010; status: terminated.
02
Drugs
secukinumab
03
Conditions
Behçet's disease (BD)uveitis
Beyond the preview
Go deeper on NCT01093846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01093846.